Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Fundación para la Investigación del Hospital Clínico de Valencia
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06824831CT.gov Use of Microporous Polysaccharide Hemispheres in Breast Cancer Patients Undergoing Mastectomy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Microporous Polysaccharide Hemospheres (this asset) | Fundación para la Investigación del Hospital Clínico de Valencia | Approved | BB · 69 |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P4 | BB |
| Exemestane | Fujian Cancer Hospital | P4 | BB |
| Adriamycin | Merck Sharp & Dohme LLC | P4 | BB |
| Docetaxel | Universitas Airlangga | P4 | BB |
| Tamoxifen | Eli Lilly and Company | P3 | BB |
| Letrozole | Fujian Cancer Hospital | P4 | BB |
| Epirubicin | Universitas Airlangga | P4 | BB |
| Palbociclib | Eli Lilly and Company | P4 | BB |
+42 more in the Breast Neoplasm cohort
Other indications for Microporous Polysaccharide Hemospheres
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P4 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Microporous Polysaccharide Hemospheres in Breast Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/microporous-polysaccharide-hemospheres-breast-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →